----
Current ValuationThe current P/E ratio is -1.24, within the reasonable range, cheaper than 33.77% of the time in the past 5 years, and the industry ranks 232/604, the industry Median -1.89.
-1.24xP/E
$1.24Stock price
$-1.00Earnings per share
-1.24xP/E
Stock price$1.24Earnings per share$-1.00
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.57x
- Typical range
- -7.40x–-0.93x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
020406080
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -58.76x | 150.48% | $190.38B |
MRNAUSModerna | -28.67x | 15.49% | $90.35B |
CSLLYUSCSL Limited | -23.97x | -- | $61.82B |
NTRAUSNatera | -295.83x | 6.85% | $56.90B |
RVMDUSRevolution Medicines | -23.46x | 62.10% | $41.48B |
ROIVUSRoivant Sciences | -91.21x | 146.49% | $24.28B |
BNTXUSBioNTech SE | -11.39x | 19.07% | $22.27B |
INSMUSInsmed | -24.40x | 74.50% | $21.36B |
BBIOUSBridgebio Pharma | -18.35x | 28.67% | $12.70B |
SMMTUSSummit Therapeutics | -14.10x | 20.67% | $12.07B |
PCVXUSVaxcyte | -9.99x | 48.18% | $10.63B |
MDGLUSMadrigal Pharma | -32.69x | 51.32% | $10.63B |
IBRXUSImmunityBio | -10.58x | 153.51% | $10.50B |
TWSTUSTwist Bioscience | -71.34x | 28.71% | $9.75B |
KYMRUSKymera Therapeutics | -29.65x | 5.24% | $8.88B |
CYTKUSCytokinetics | -9.86x | 6.68% | $8.82B |
ARWRUSArrowHead Pharma | -25.77x | 35,923.70% | $8.25B |
ABVXUSAbivax SA | -16.49x | 22.49% | $7.67B |
IONSUSIonis Pharma | -12.56x | 50.43% | $7.10B |
SYREUSSpyre Therapeutics | -46.16x | 45.67% | $6.93B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
